See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Summary by Missoulian
Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study

20 Articles

Montana StandardMontana Standard
+19 Reposted by 19 other sources
Center

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 91% of the sources are Center
91% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Missoulian broke the news in Missoula, United States on Thursday, August 7, 2025.
Sources are mostly out of (0)

Similar News Topics

Montana, United States icon

Montana, United States

News
For You
SearchBlindspotLocal